---
title: "Nystagmus Evaluation"
description: "Clinical decision support for systematic nystagmus evaluation, classification, and management"
version: "1.1"
setting: "ED, HOSP, OPD, ICU"
status: draft
tags:
  - nystagmus
  - vestibular
  - neuro-ophthalmology
  - oculomotor
  - central
  - peripheral
---

<div class="draft-warning-banner">
  <div class="icon">⚠️</div>
  <div class="content">
    <div class="title">DRAFT - Pending Review</div>
    <div class="description">This plan requires physician review before clinical use.</div>
  </div>
</div>

# Nystagmus Evaluation

**VERSION:** 1.1
**CREATED:** February 2, 2026
**REVISED:** February 2, 2026
**STATUS:** Revised per checker validation (v1.1)

---

**DIAGNOSIS:** Nystagmus Evaluation

**ICD-10:** H55.00 (Unspecified nystagmus), H55.01 (Congenital nystagmus), H55.02 (Latent nystagmus), H55.09 (Other forms of nystagmus), H55.89 (Other irregular eye movements), H81.4 (Vertigo of central origin), G45.0 (Vertebro-basilar artery syndrome), R29.810 (Facial weakness), G25.3 (Myoclonus), G11.9 (Hereditary ataxia, unspecified)

**CPT CODES:** 92540 (Electronystagmography/videonystagmography), 92541 (Spontaneous nystagmus test), 92542 (Positional nystagmus test), 92544 (Optokinetic nystagmus test), 92545 (Oscillating tracking test), 92546 (Sinusoidal rotational testing), 92547 (Supplemental caloric test), 92548 (Computerized dynamic posturography), 92517 (VEMP), 92270 (Electro-oculography), 70553 (MRI brain with/without contrast), 70551 (MRI brain without contrast), 70544 (MRA head), 70547 (MRA neck), 70496 (CTA head), 70498 (CTA neck), 95816 (EEG routine), 95819 (EEG with sleep), 92557 (Audiometry), 95930 (Visual evoked potential), 99213-99215 (Outpatient E/M), 99281-99285 (ED E/M)

**SYNONYMS:** Nystagmus, involuntary eye movements, oscillopsia, nystagmus evaluation, dancing eyes, gaze-evoked nystagmus, downbeat nystagmus, upbeat nystagmus, periodic alternating nystagmus, PAN, direction-changing nystagmus, vestibular nystagmus, positional nystagmus, jerk nystagmus, pendular nystagmus, see-saw nystagmus, convergence-retraction nystagmus, acquired nystagmus

**SCOPE:** Systematic evaluation and management of acquired nystagmus in adults. Covers classification (central vs. peripheral), bedside examination techniques (HINTS exam, gaze testing, positional maneuvers), differentiation of nystagmus subtypes (gaze-evoked, downbeat, upbeat, periodic alternating, see-saw, convergence-retraction, vestibular), VNG/ENG and advanced vestibular testing, neuroimaging indications, and targeted treatment of specific nystagmus types (4-aminopyridine for downbeat nystagmus, baclofen for periodic alternating nystagmus, gabapentin/memantine for acquired pendular nystagmus). Excludes congenital/infantile nystagmus (brief mention), physiologic endpoint nystagmus, and comprehensive vertigo/dizziness evaluation (see Vertigo/Dizziness Evaluation template).

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

═══════════════════════════════════════════════════════════════
SECTION A: ACTION ITEMS
═══════════════════════════════════════════════════════════════

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs

| Test | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------|:--:|:----:|:---:|:---:|-----------|----------------|
| CBC (CPT 85025) | STAT | STAT | ROUTINE | STAT | Infection screening; anemia (exacerbates dizziness/oscillopsia); baseline before treatment | Normal; infection markers; anemia correction |
| CMP (BMP + LFTs) (CPT 80053) | STAT | STAT | ROUTINE | STAT | Electrolyte abnormalities (hyponatremia causes central nystagmus); hepatic/renal dysfunction affects drug metabolism; hypomagnesemia lowers threshold | Normal; hyponatremia <130 — correct and reassess nystagmus; hepatic dysfunction — medication adjustment |
| Blood glucose (CPT 82947) | STAT | STAT | ROUTINE | STAT | Hypoglycemia causes neurologic symptoms including nystagmus; Wernicke encephalopathy association | 70-180 mg/dL; hypoglycemia — correct; persistent low — evaluate further |
| Magnesium (CPT 83735) | STAT | STAT | ROUTINE | STAT | Hypomagnesemia causes nystagmus and cerebellar dysfunction; depleted by alcohol, diuretics, PPI use | >2.0 mg/dL; low — replete IV/PO |
| TSH (CPT 84443) | - | ROUTINE | ROUTINE | - | Thyroid dysfunction affects vestibular and oculomotor function; hyperthyroidism causes tremor/jerky saccades | Normal; abnormal — thyroid evaluation |
| Thiamine (B1) level (CPT 84425) | STAT | STAT | ROUTINE | STAT | Wernicke encephalopathy (nystagmus + ataxia + confusion); ALWAYS suspect in alcoholism, malnutrition, bariatric surgery, hyperemesis | Normal; **DO NOT WAIT for level before treating** — empiric thiamine if suspected |
| Anticonvulsant drug levels (if applicable) (CPT 80201-80299) | STAT | STAT | ROUTINE | STAT | Phenytoin, carbamazepine, and lacosamide toxicity cause gaze-evoked nystagmus; lithium toxicity causes downbeat nystagmus | Therapeutic range; supratherapeutic — dose reduction; toxic — hold medication |
| Ethanol level (CPT 80307) | STAT | STAT | - | STAT | Acute alcohol intoxication causes gaze-evoked and positional nystagmus; chronic alcoholism — Wernicke/cerebellar degeneration | Negative; positive — quantify; treat Wernicke empirically |

### 1B. Extended Workup (Second-line)

| Test | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------|:--:|:----:|:---:|:---:|-----------|----------------|
| Vitamin B12 (CPT 82607) | - | ROUTINE | ROUTINE | - | B12 deficiency causes subacute combined degeneration with ataxia and nystagmus | >300 pg/mL; low — supplement and monitor |
| Folate (CPT 82746) | - | ROUTINE | ROUTINE | - | Folate deficiency contributes to cerebellar dysfunction, especially in alcoholism | >4 ng/mL; low — supplement |
| Vitamin E level (CPT 82446) | - | - | ROUTINE | - | Vitamin E deficiency causes spinocerebellar syndrome with nystagmus; malabsorption syndromes | Normal; low — supplement and evaluate malabsorption |
| ESR (CPT 85652) / CRP (CPT 86140) | - | ROUTINE | ROUTINE | - | Inflammatory/autoimmune processes (MS, neurosarcoidosis, vasculitis) causing central nystagmus | Normal; elevated — autoimmune/inflammatory workup |
| ANA (CPT 86235) | - | ROUTINE | ROUTINE | - | Autoimmune conditions causing CNS inflammation (SLE cerebritis, neurosarcoidosis) | Negative; positive — further autoimmune serologies |
| ACE level (CPT 82164) | - | ROUTINE | ROUTINE | - | Neurosarcoidosis causes brainstem/cerebellar lesions with nystagmus | Normal; elevated — chest imaging, evaluate for neurosarcoidosis |
| RPR/VDRL (CPT 86592) | - | ROUTINE | ROUTINE | - | Neurosyphilis causes Argyll Robertson pupils and nystagmus; tabes dorsalis | Negative; positive — FTA-ABS confirmation, CSF analysis |
| Anti-GAD65 antibodies (CPT 86235) | - | - | ROUTINE | - | GAD65 autoimmunity causes cerebellar ataxia with downbeat nystagmus; progressive cerebellar syndrome | Negative; positive — autoimmune cerebellar disease; initiate immunotherapy |
| Paraneoplastic antibody panel (anti-Yo, anti-Hu, anti-Tr/DNER, anti-CV2, anti-mGluR1) | - | - | ROUTINE | - | Paraneoplastic cerebellar degeneration presents with nystagmus (often downbeat) + progressive ataxia | Negative; positive — urgent malignancy search (CT chest/abdomen/pelvis, PET) |

### 1C. Rare/Specialized (Refractory or Atypical)

| Test | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------|:--:|:----:|:---:|:---:|-----------|----------------|
| Anti-CASPR2 / Anti-LGI1 antibodies | - | - | EXT | - | Autoimmune encephalitis with oculomotor abnormalities; limbic encephalitis with nystagmus | Negative; positive — autoimmune encephalitis workup, immunotherapy |
| Anti-IgLON5 antibodies | - | - | EXT | - | Anti-IgLON5 disease causes oculomotor dysfunction including nystagmus, sleep disorder, gait ataxia | Negative; positive — sleep study, tau pathology evaluation |
| Genetic testing (SCA panel, episodic ataxia genes) | - | - | EXT | - | Spinocerebellar ataxias (SCA1, 2, 3, 6, 7); episodic ataxia type 2 (CACNA1A); Friedreich ataxia | Specific mutations; SCA6 and EA2 both involve CACNA1A; SCA — progressive; EA2 — episodic with interictal nystagmus |
| CSF analysis (see Lumbar Puncture section) | - | EXT | EXT | - | MS (oligoclonal bands), neurosarcoidosis, leptomeningeal disease, CNS infection, autoimmune encephalitis | Normal in degenerative; OCBs — MS; pleocytosis — infection/inflammation; cytology — malignancy |
| Serum copper / ceruloplasmin (CPT 82525 / 82390) | - | - | EXT | - | Wilson disease causes wing-beating tremor and oculomotor dysfunction including nystagmus in young adults | Normal ceruloplasmin >20 mg/dL; low — 24h urine copper, slit lamp for KF rings |
| Tissue transglutaminase (tTG-IgA) (CPT 86364) | - | - | EXT | - | Celiac disease causes cerebellar ataxia with nystagmus ("gluten ataxia") even without GI symptoms | Negative; positive — gluten-free diet, anti-gliadin antibodies |
| Prion protein gene (PRNM) analysis | - | - | EXT | - | Gerstmann-Straussler-Scheinker syndrome; genetic CJD presents with cerebellar ataxia and nystagmus | No pathogenic mutation; mutation — genetic counseling |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| **Bedside nystagmus characterization** | STAT | STAT | ROUTINE | STAT | **CRITICAL first step**; systematic assessment: gaze in 9 cardinal positions, fixation removal (Frenzel goggles), head-shaking nystagmus, positional testing, HINTS exam if acute vestibular syndrome | Nystagmus pattern classification (see Section 5 — Differential Diagnosis); direction, waveform, effect of fixation, positional component | None; requires trained examiner |
| **HINTS exam (Head Impulse, Nystagmus, Test of Skew)** | STAT | STAT | - | STAT | **ONLY for acute vestibular syndrome** (continuous vertigo + nystagmus >24h); more sensitive than early MRI for posterior fossa stroke; trained examiner required | **Peripheral:** Positive HIT + unidirectional nystagmus + no skew; **Central:** Normal HIT + direction-changing/vertical nystagmus + skew deviation — STAT MRI | Not valid for episodic or positional nystagmus; requires acute continuous nystagmus; examiner training required |
| MRI brain with and without contrast (CPT 70553) | URGENT | URGENT | ROUTINE | URGENT | **Gold standard for central nystagmus evaluation**; includes DWI for stroke, FLAIR for demyelination, thin cuts through posterior fossa; MRI protocol includes craniocervical junction (downbeat nystagmus — Chiari malformation) | Stroke (DWI restriction); MS plaques (brainstem/cerebellum); Chiari malformation (cerebellar tonsillar herniation >5 mm); tumor (vestibular schwannoma, brainstem glioma, cerebellar metastasis); cerebellar degeneration (atrophy) | MRI-incompatible implants; severe claustrophobia; renal impairment (for gadolinium) |
| CT head without contrast (CPT 70450) | STAT | STAT | - | STAT | **NOT sensitive for posterior fossa pathology** (beam-hardening artifact); use only if MRI unavailable or for acute hemorrhage screening; does NOT rule out posterior circulation stroke or demyelination | Hemorrhage; large mass; hydrocephalus; **NEGATIVE CT does NOT exclude posterior fossa pathology** | None for non-contrast |
| MRA head and neck (CPT 70544, 70547) or CTA head/neck (CPT 70496, 70498) | URGENT | URGENT | ROUTINE | URGENT | If central nystagmus with stroke concern; vertebral artery dissection; basilar artery stenosis/occlusion; vertebrobasilar insufficiency | Vertebral/basilar artery dissection; stenosis; occlusion; dolichoectasia compressing brainstem | MRA: MRI contraindications; CTA: contrast allergy, renal impairment |

### 2B. Extended

| Study | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| Videonystagmography (VNG) (CPT 92540-92547) | - | - | ROUTINE | - | Comprehensive oculomotor and vestibular testing; spontaneous nystagmus, gaze testing, positional testing, Dix-Hallpike, caloric testing; quantifies nystagmus; documents central vs. peripheral patterns | Gaze-evoked nystagmus (central); unilateral caloric weakness (peripheral); direction-changing positional nystagmus (central); fixation suppression failure (central) | Perforated TM (water calorics — use air); bilateral vestibular loss limits caloric utility |
| Video head impulse test (vHIT) (CPT 92517) | - | URGENT | ROUTINE | - | Quantitative VOR assessment for all 6 semicircular canals; more sensitive than bedside HIT; differentiates peripheral from central vestibular lesions | Reduced VOR gain (<0.8) with corrective saccades — peripheral lesion; normal gain with central nystagmus — central lesion; canal-specific identification | Specialized equipment required |
| Audiometry (CPT 92557) | - | URGENT | ROUTINE | - | Hearing assessment when vestibular nystagmus present; identifies Meniere's disease, vestibular schwannoma, labyrinthitis; sudden sensorineural hearing loss is emergency | Normal (isolated nystagmus); low-frequency SNHL — Meniere's; asymmetric SNHL — vestibular schwannoma; mixed hearing loss — SSCD | Patient cooperation |
| MRI internal auditory canals (IAC protocol) (CPT 70553) | - | ROUTINE | ROUTINE | - | High-resolution T2 (CISS/FIESTA) for vestibular schwannoma; vascular loop compression of CN VIII; when asymmetric hearing loss or unilateral vestibular nystagmus | Vestibular schwannoma; vascular loop; arachnoid cyst | MRI contraindications |
| Dix-Hallpike maneuver (CPT 95992) | STAT | STAT | ROUTINE | - | When positional nystagmus suspected (BPPV); upbeat-torsional nystagmus with latency and limited duration = posterior canal BPPV | **Positive:** Upbeating-torsional nystagmus, 2-20 sec latency, <60 sec duration, fatigable — posterior canal BPPV; **Atypical:** No latency, persistent, non-fatigable — central positional nystagmus | Cervical spine instability; severe carotid stenosis (modify technique) |
| Visual evoked potential (VEP) (CPT 95930) | - | - | ROUTINE | - | If MS suspected; optic nerve demyelination; confirms optic nerve involvement in clinically isolated syndrome | Prolonged P100 latency — optic nerve demyelination (even subclinical); supports MS diagnosis | Patient cooperation; severe visual impairment |
| EEG (CPT 95816/95819) | - | ROUTINE | ROUTINE | ROUTINE | If seizure-related nystagmus (oculogyric episodes) or epileptic nystagmus suspected; also if episodic nystagmus with altered awareness | Normal; epileptiform discharges; seizure-related eye deviation | None |

### 2C. Rare/Advanced

| Study | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| Vestibular evoked myogenic potentials (VEMP) (CPT 92517) | - | - | ROUTINE | - | Saccular (cVEMP) and utricular (oVEMP) function; superior semicircular canal dehiscence; Meniere's disease; vestibular schwannoma | Abnormal in SSCD (enhanced cVEMP/oVEMP); reduced/absent in vestibular schwannoma; asymmetric in Meniere's | Conductive hearing loss affects testing |
| Rotary chair testing (CPT 92546) | - | - | EXT | - | Quantitative VOR across frequencies; bilateral vestibular hypofunction; pharmaceutical ototoxicity monitoring | Bilateral vestibular loss (reduced gain across frequencies); phase/gain abnormalities; asymmetric VOR | Specialized facility required |
| High-resolution CT temporal bones (CPT 70480) | - | - | ROUTINE | - | Superior semicircular canal dehiscence syndrome; cholesteatoma; temporal bone fracture; when sound/pressure-induced nystagmus | Dehiscence of superior canal; bony erosion; fracture line | Radiation exposure |
| Optical coherence tomography (OCT) | - | - | ROUTINE | - | Retinal nerve fiber layer thinning in chronic MS, neurodegenerative conditions; baseline for monitoring | RNFL thinning — chronic optic neuropathy; normal in acute | Patient cooperation; media opacity |
| Saccadometry / Eye movement recording | - | - | EXT | - | Quantitative analysis of saccades, smooth pursuit, optokinetic nystagmus; distinguish types of cerebellar oculomotor dysfunction | Saccadic dysmetria; impaired pursuit; gaze-holding failure; specific patterns for cerebellar vs. brainstem lesions | Specialized equipment |
| MRI cervical spine (CPT 72141/72156) | - | ROUTINE | ROUTINE | - | If downbeat nystagmus — evaluate craniocervical junction; Chiari malformation, craniocervical instability, foramen magnum lesion | Chiari I malformation (tonsillar herniation >5 mm); foramen magnum tumor; basilar invagination; syrinx | MRI contraindications |

### Lumbar Puncture

| Study | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| LP — Selective indication | - | EXT | EXT | - | Indicated if MS, neurosarcoidosis, autoimmune encephalitis, CNS infection, or leptomeningeal disease suspected; NOT routine for isolated nystagmus; perform after MRI | Opening pressure normal (10-20 cm H2O); **MS:** oligoclonal bands, elevated IgG index; **Neurosarcoid:** pleocytosis, elevated protein, low glucose; **Infection:** per organism; **Autoimmune:** specific antibodies | Posterior fossa mass on imaging; elevated ICP without imaging; coagulopathy |

---

## 3. TREATMENT PROTOCOLS

### 3A. Acute/Emergent Treatment

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| **Thiamine (empiric if Wernicke suspected)** | IV | Wernicke encephalopathy (nystagmus + ataxia + confusion triad; may be incomplete) | 500 mg :: IV :: TID :: **Thiamine 500 mg IV TID x 3-5 days, then 250 mg IV daily x 3-5 days, then 100 mg PO daily indefinitely**; give BEFORE glucose; [Galvin et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20459462/) | None at therapeutic doses | Monitor clinical improvement in nystagmus, ataxia, confusion; improvement within hours to days supports diagnosis; anaphylaxis rare with IV thiamine | STAT | STAT | - | STAT |
| **Correct electrolyte abnormalities** | IV | Hyponatremia, hypomagnesemia, hypocalcemia causing nystagmus | Per specific electrolyte :: IV :: per protocol :: **Hyponatremia:** Correct slowly (max 8-10 mEq/L per 24h to avoid osmotic demyelination); **Hypomagnesemia:** MgSO4 2-4 g IV over 30-60 min then maintenance; **Hypocalcemia:** Calcium gluconate 1-2 g IV | Overcorrection of sodium — osmotic demyelination syndrome | Electrolytes q4-6h during correction; neurologic reassessment after correction | STAT | STAT | ROUTINE | STAT |
| **Discontinue/reduce offending medication** | - | Drug-induced nystagmus (anticonvulsants, lithium, sedatives, aminoglycosides) | Hold or reduce dose :: - :: per protocol :: **Phenytoin toxicity:** Hold doses until level <20 mcg/mL; **Carbamazepine toxicity:** Hold until level <12 mcg/mL; **Lithium toxicity:** Hold; hydration; hemodialysis if severe; **Aminoglycosides:** Discontinue if vestibulotoxicity confirmed | Clinical necessity of medication; consult prescribing specialist | Drug levels; nystagmus reassessment after dose adjustment; permanent vestibulotoxicity possible with aminoglycosides | STAT | STAT | ROUTINE | STAT |
| **Rule out posterior circulation stroke** | - | Acute-onset nystagmus with ANY central features (direction-changing, vertical, gaze-evoked without drug cause, skew deviation, normal HIT) | HINTS exam :: - :: immediate :: **If ANY central pattern on HINTS:** STAT MRI with DWI + MRA head/neck; neurology/stroke consultation; activate stroke protocol if within window; [Kattah et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19762709/) | Do not delay for MRI if basilar artery occlusion suspected | HINTS more sensitive than early CT or MRI for posterior fossa stroke; negative CT does NOT exclude stroke | STAT | STAT | - | STAT |
| **Meclizine** | PO | Acute peripheral vestibular nystagmus with oscillopsia, nausea, or vertigo; **SHORT-TERM ONLY (24-72h)**; avoid in central nystagmus until etiology established | 25 mg :: PO :: q6-8h :: **Meclizine 25 mg PO q6-8h PRN**; limit to 48-72h maximum; taper as tolerated | Avoid in central nystagmus until etiology established; prolonged use delays vestibular compensation; anticholinergic effects in elderly; urinary retention; glaucoma | Limit to 72h; sedation; early vestibular rehabilitation once acute phase resolved | STAT | STAT | ROUTINE | - |
| **Dimenhydrinate** | PO/IV | Acute peripheral vestibular nystagmus with nausea and vertigo; **SHORT-TERM ONLY (24-72h)**; avoid in central nystagmus until etiology established | 50 mg :: PO/IV :: q6h :: **Dimenhydrinate 50 mg PO or IV q6h PRN**; limit to 48-72h maximum | Avoid in central nystagmus until etiology established; prolonged use delays vestibular compensation; anticholinergic effects in elderly; sedation | Limit to 72h; sedation; anticholinergic side effects | STAT | STAT | ROUTINE | - |
| **Diazepam** | PO/IV | Acute vestibular nystagmus with severe vertigo; potent vestibular suppressant; **SHORT-TERM ONLY (24-72h)** | 2 mg :: PO/IV :: q8h :: **Diazepam 2-5 mg PO or IV q8h PRN**; limit to 48-72h maximum; taper rapidly | Respiratory depression; CNS depression; avoid in elderly; avoid in hepatic impairment; dependency risk | Respiratory status; sedation level; fall risk; limit to 72h; avoid in suspected central cause until stroke excluded | STAT | STAT | - | STAT |
| **Ondansetron** | IV/PO | Nausea and vomiting associated with acute vestibular nystagmus; antiemetic without vestibular suppressant effect | 4 mg :: IV/PO :: q8h :: **Ondansetron 4-8 mg IV or PO q8h PRN for nausea** | QT prolongation; serotonin syndrome risk with serotonergic agents; hepatic impairment (max 8 mg/day) | QTc monitoring if prolonged use; constipation | STAT | STAT | ROUTINE | STAT |

### 3B. Type-Specific Nystagmus Treatment

#### DOWNBEAT NYSTAGMUS

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| **4-Aminopyridine (4-AP, dalfampridine)** | PO | First-line for symptomatic downbeat nystagmus; potassium channel blocker that improves Purkinje cell function | 5 mg :: PO :: BID :: **4-Aminopyridine 5 mg PO BID (compounded)** or **Dalfampridine (Ampyra) 10 mg PO BID** (extended-release); [Strupp et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12847523/); [Claassen et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23460616/) | **Seizure disorder** (lowers seizure threshold); renal impairment (CrCl <50 — dose adjustment); hepatic impairment; cardiac arrhythmia (prolongs QT at supratherapeutic doses) | Seizure risk; ECG at baseline; renal function; therapeutic response assessment at 2-4 weeks; visual acuity improvement | - | URGENT | ROUTINE | - |
| **3,4-Diaminopyridine (3,4-DAP, amifampridine)** | PO | Alternative to 4-AP for downbeat nystagmus; lower seizure risk than 4-AP | 10 mg :: PO :: TID :: **3,4-Diaminopyridine 10 mg PO TID, titrate to max 20 mg TID (80 mg/day)**; [Kalla et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17928582/) | Seizure disorder (lower risk than 4-AP but still present); QT prolongation | Seizure monitoring; ECG; clinical response | - | ROUTINE | ROUTINE | - |
| **Clonazepam** | PO | Second-line for downbeat nystagmus; GABAergic effect on vestibular nuclei | 0.5 mg :: PO :: BID :: **Clonazepam 0.5 mg PO BID, titrate to max 1 mg TID**; improves oscillopsia; [Dieterich et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/2052574/) | Sedation; respiratory depression; falls in elderly; dependency with long-term use; cognitive impairment | Sedation; fall risk; respiratory status; avoid abrupt discontinuation; limit duration | - | ROUTINE | ROUTINE | - |
| **Baclofen** | PO | Third-line for downbeat nystagmus; GABAergic mechanism | 5 mg :: PO :: TID :: **Baclofen 5 mg PO TID, titrate to 10-20 mg TID**; less evidence than 4-AP | Renal impairment; sedation; withdrawal seizures if abruptly stopped | Sedation; muscle weakness; renal function; slow taper if discontinuing | - | ROUTINE | ROUTINE | - |
| **Address underlying cause** | - | Chiari malformation; craniocervical junction pathology; MS; cerebellar degeneration | Per etiology :: - :: per diagnosis :: **Chiari malformation:** Neurosurgical referral for posterior fossa decompression if symptomatic; **MS:** Disease-modifying therapy; **Paraneoplastic:** Immunotherapy + malignancy treatment; **Nutritional:** Vitamin supplementation | Per specific intervention | Nystagmus may improve or persist depending on degree of irreversible cerebellar damage | - | ROUTINE | ROUTINE | - |

#### UPBEAT NYSTAGMUS

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| **4-Aminopyridine (4-AP)** | PO | Upbeat nystagmus (less evidence than for downbeat, but reasonable trial); improves oculomotor function | 5 mg :: PO :: BID :: **4-AP 5 mg PO BID**; trial for 2-4 weeks to assess benefit; [Glasauer et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15721220/) | Seizure disorder (lowers seizure threshold); renal impairment (CrCl <50 — dose adjustment); hepatic impairment; cardiac arrhythmia (QT prolongation at supratherapeutic doses) | Seizure risk; therapeutic response; ECG at baseline; renal function | - | ROUTINE | ROUTINE | - |
| **Baclofen** | PO | Alternative for upbeat nystagmus; GABAergic modulation | 5 mg :: PO :: TID :: **Baclofen 5-10 mg PO TID, titrate to 20 mg TID** | Renal impairment; sedation; withdrawal seizures/hallucinations if abruptly discontinued; concurrent CNS depressants | Sedation; muscle weakness; withdrawal risk; gradual taper required for discontinuation | - | ROUTINE | ROUTINE | - |
| **Treat underlying etiology** | - | Medullary lesion (most common); Wernicke encephalopathy; MS; brainstem tumor; meningitis | Per etiology :: - :: per diagnosis :: **Wernicke:** Thiamine 500 mg IV TID (see 3A); **MS:** IV methylprednisolone 1 g daily x 3-5 days for acute relapse + DMT; **Tumor:** Oncologic referral; **Stroke:** Stroke protocol | Per specific treatment | Nystagmus may resolve with treatment of underlying cause, especially Wernicke and MS | STAT | STAT | ROUTINE | STAT |

#### PERIODIC ALTERNATING NYSTAGMUS (PAN)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| **Baclofen** | PO | **First-line for periodic alternating nystagmus**; GABA-B agonist disrupts the oscillatory brainstem velocity storage mechanism | 5 mg :: PO :: TID :: **Baclofen 5 mg PO TID, titrate by 5 mg every 3 days to 10-20 mg TID (max 80 mg/day)**; highly effective for PAN; [Halmagyi et al. (1980)](https://pubmed.ncbi.nlm.nih.gov/7191854/); [Leigh & Zee (2015)](https://pubmed.ncbi.nlm.nih.gov/26160853/) | Renal impairment; sedation; withdrawal seizures/hallucinations if abruptly discontinued; concurrent use of other CNS depressants | Sedation; muscle weakness; gradual taper required for discontinuation; monitor nystagmus response within 1-2 weeks | - | URGENT | ROUTINE | - |
| **4-Aminopyridine (4-AP)** | PO | Second-line for PAN if baclofen not tolerated or insufficient | 5 mg :: PO :: BID :: **4-AP 5 mg PO BID**; may combine with baclofen; [Strupp et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12847523/) | Seizure disorder (lowers seizure threshold); renal impairment (CrCl <50 — dose adjustment); cardiac arrhythmia (QT prolongation) | Seizure monitoring; ECG; clinical response | - | ROUTINE | ROUTINE | - |
| **Memantine** | PO | Third-line for PAN; NMDA receptor antagonist affects velocity storage | 5 mg :: PO :: daily :: **Memantine 5 mg PO daily, titrate by 5 mg weekly to 10 mg BID**; limited evidence but rational mechanism | Renal impairment; seizure history | Renal function; confusion; dizziness | - | - | ROUTINE | - |

#### GAZE-EVOKED NYSTAGMUS

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| **Remove offending agent** | - | Drug-induced gaze-evoked nystagmus (most common cause; anticonvulsants, sedatives, alcohol) | Reduce dose or discontinue :: - :: immediate :: **Most common cause is medication toxicity**; phenytoin, carbamazepine, lacosamide, benzodiazepines, lithium, gabapentin at supratherapeutic doses; nystagmus resolves with dose reduction | Clinical necessity of medication | Drug levels; clinical resolution typically within 24-48h of dose correction | STAT | STAT | ROUTINE | STAT |
| **4-Aminopyridine** | PO | Gaze-evoked nystagmus from cerebellar pathology (not drug-induced); improves gaze-holding function | 5 mg :: PO :: BID :: **4-AP 5 mg PO BID**; helps with cerebellar integrator dysfunction | Seizure disorder (lowers seizure threshold); renal impairment (CrCl <50 — dose adjustment); cardiac arrhythmia (QT prolongation) | Clinical response; seizure monitoring; ECG at baseline | - | ROUTINE | ROUTINE | - |
| **Treat structural cause** | - | Cerebellar lesion, brainstem lesion, MS, Chiari malformation | Per etiology :: - :: per diagnosis :: MRI-guided management; neurosurgical referral for mass lesions; DMT for MS | Per specific treatment | Gaze-evoked nystagmus from structural lesions may persist despite treatment | - | ROUTINE | ROUTINE | - |

#### SEE-SAW NYSTAGMUS

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| **Treat underlying cause** | - | Parasellar/diencephalic lesion (craniopharyngioma, pituitary macroadenoma, septo-optic dysplasia); rarely brainstem stroke | Per etiology :: - :: per diagnosis :: **Parasellar mass:** Neurosurgical resection or debulking; endocrine evaluation; visual field assessment; **Stroke:** Standard stroke management | Per intervention | Visual acuity; visual fields; endocrine function; nystagmus may persist after tumor removal | - | URGENT | ROUTINE | - |
| **Clonazepam** | PO | Symptomatic relief of oscillopsia from see-saw nystagmus; limited evidence; trial basis | 0.5 mg :: PO :: BID :: **Clonazepam 0.5 mg PO BID, titrate to max 1 mg TID** | Sedation; respiratory depression; falls in elderly; dependency with long-term use; cognitive impairment | Sedation; fall risk; respiratory status; response assessment; avoid abrupt discontinuation | - | ROUTINE | ROUTINE | - |
| **Baclofen** | PO | Symptomatic relief of oscillopsia from see-saw nystagmus; limited evidence; trial basis | 10 mg :: PO :: TID :: **Baclofen 10 mg PO TID, titrate to 20 mg TID** | Renal impairment; sedation; withdrawal seizures/hallucinations if abruptly discontinued; concurrent CNS depressants | Sedation; muscle weakness; response assessment; gradual taper required for discontinuation | - | ROUTINE | ROUTINE | - |

#### ACQUIRED PENDULAR NYSTAGMUS

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| **Gabapentin** | PO | First-line for acquired pendular nystagmus (MS-associated); reduces oscillopsia; [Starck et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9109746/) | 300 mg :: PO :: TID :: **Gabapentin 300 mg PO TID; titrate by 300 mg/day every 3-5 days to 900-1200 mg TID (max 3600 mg/day)** | Renal impairment (CrCl-based dose adjustment); sedation; respiratory depression when combined with CNS depressants | Sedation; dizziness; peripheral edema; renal function; clinical response at 2-4 weeks | - | ROUTINE | ROUTINE | - |
| **Memantine** | PO | Alternative first-line for acquired pendular nystagmus (MS-associated); NMDA receptor antagonist; [Starck et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9109746/) | 5 mg :: PO :: daily :: **Memantine 5 mg PO daily, titrate by 5 mg weekly to 10 mg BID** | Renal impairment (dose adjustment if CrCl <30); seizure history | Renal function; confusion; dizziness; clinical response at 2-4 weeks | - | ROUTINE | ROUTINE | - |
| **Treat underlying MS** | - | MS-associated acquired pendular nystagmus; disease-modifying therapy and acute relapse management | Per MS treatment protocol :: - :: per diagnosis :: **Acute relapse:** IV methylprednisolone 1 g daily x 3-5 days; **Chronic:** Disease-modifying therapy per MS guidelines | Per specific DMT | MS disease activity; nystagmus severity; OCT for optic nerve monitoring | - | ROUTINE | ROUTINE | - |

#### CONVERGENCE-RETRACTION NYSTAGMUS

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| **Treat underlying cause (dorsal midbrain lesion)** | - | Dorsal midbrain syndrome (Parinaud syndrome) from pineal tumor, hydrocephalus, MS, or brainstem stroke | Per etiology :: - :: per diagnosis :: **Pineal tumor:** Neurosurgical referral for resection/biopsy/shunt; oncology consultation; **Hydrocephalus:** CSF diversion (VP shunt or ETV); **MS:** DMT + IV steroids for acute relapse; **Stroke:** Standard stroke management | Per specific intervention | Upgaze function; pupillary reactivity; convergence-retraction nystagmus resolution; ICP monitoring if hydrocephalus | STAT | URGENT | ROUTINE | STAT |

### 3C. Medications to AVOID or Use with Caution

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| **Vestibular suppressants (prolonged use >72h)** | PO | Delays central compensation; masks underlying pathology; sedation; fall risk | Avoid use beyond 72h :: - :: - :: Limit to 48-72h for acute peripheral vestibular nystagmus; NOT indicated for central nystagmus types | - | Monitor duration of use; initiate vestibular rehabilitation early | - | - | - | - |
| **Aminoglycosides** (gentamicin, tobramycin, streptomycin) | IV/IM | Vestibulotoxic — causes permanent bilateral vestibular hypofunction with oscillopsia; irreversible | Avoid if possible :: IV/IM :: - :: If aminoglycoside absolutely necessary, monitor peak/trough levels strictly; discontinue if vestibular symptoms develop | Pre-existing vestibular dysfunction; concurrent ototoxic agents | Peak/trough levels; vestibular symptom assessment; audiometry if prolonged course | STAT | STAT | ROUTINE | STAT |
| **Phenytoin (high-dose / supratherapeutic)** | PO/IV | Nystagmus is dose-dependent toxicity sign; gaze-evoked nystagmus appears before ataxia; monitor levels | Monitor levels :: PO/IV :: - :: Free phenytoin level; nystagmus = early toxicity warning; reduce dose immediately if nystagmus develops | - | Free phenytoin level; nystagmus is early warning sign of toxicity | STAT | STAT | ROUTINE | STAT |
| **Lithium (supratherapeutic)** | PO | Downbeat nystagmus and cerebellar toxicity; may be irreversible ("SILENT syndrome" — syndrome of irreversible lithium-effectuated neurotoxicity) | Monitor levels :: PO :: - :: Lithium level STAT if nystagmus develops in lithium-treated patient; irreversible cerebellar damage possible | - | Lithium level; nystagmus in lithium-treated patient — STAT level; monitor for SILENT syndrome | STAT | STAT | ROUTINE | STAT |
| **Carbamazepine (supratherapeutic)** | PO | Gaze-evoked nystagmus and ataxia at toxic levels; dose-dependent | Monitor levels :: PO :: - :: Drug level; reduce dose; autoinduction may alter levels unpredictably | - | Carbamazepine level; monitor for autoinduction; reduce dose if nystagmus develops | STAT | STAT | ROUTINE | STAT |

---

## 4. OTHER RECOMMENDATIONS

### 4A. Referrals & Consults

| Recommendation | ED | HOSP | OPD | ICU |
|---------------|:--:|:----:|:---:|:---:|
| Systematic nystagmus characterization: document direction, waveform (jerk vs. pendular), effect of gaze position, effect of fixation removal (Frenzel goggles), effect of convergence, effect of head position; this determines central vs. peripheral and guides workup | STAT | STAT | ROUTINE | STAT |
| Frenzel goggles / fixation removal: **Critical for evaluation**; peripheral vestibular nystagmus INCREASES with fixation removal; central nystagmus is NOT suppressed by fixation; if no Frenzel goggles — have patient close eyes and observe for deviation, or use ophthalmoscope on one eye | STAT | STAT | ROUTINE | STAT |
| Neurology consultation: all central nystagmus patterns; downbeat, upbeat, see-saw, convergence-retraction, direction-changing nystagmus; gaze-evoked nystagmus without drug cause; atypical positional nystagmus | URGENT | URGENT | ROUTINE | URGENT |
| Neuro-ophthalmology referral: persistent or unexplained nystagmus; oscillopsia affecting daily function; see-saw nystagmus; convergence-retraction nystagmus; complex oculomotor patterns; need for quantitative eye movement recording | - | ROUTINE | ROUTINE | - |
| Stroke consultation: if HINTS exam suggests central pattern in acute vestibular syndrome; any acute-onset central nystagmus pattern with vascular risk factors | STAT | STAT | - | STAT |
| ENT / Neurotology referral: peripheral vestibular nystagmus with hearing loss; recurrent BPPV; suspected Meniere's; intratympanic therapy evaluation | - | ROUTINE | ROUTINE | - |
| Vestibular rehabilitation referral: all patients with persistent oscillopsia or vestibular nystagmus; gaze stabilization exercises; balance training; habituation | - | ROUTINE | ROUTINE | - |
| Fall precautions: nystagmus with oscillopsia causes gait instability; assist with ambulation; home safety assessment; walker if needed | STAT | STAT | ROUTINE | STAT |
| Ophthalmology referral: visual acuity assessment; retinal evaluation; optic disc examination; OCT if optic neuropathy suspected | - | ROUTINE | ROUTINE | - |

### 4B. Patient Instructions

| Recommendation | ED | HOSP | OPD |
|---------------|:--:|:----:|:---:|
| Nystagmus explanation: your eyes are making involuntary movements that can cause blurred vision and a sensation that things are moving (oscillopsia); this is being evaluated to find and treat the cause | ROUTINE | ROUTINE | ROUTINE |
| Medication adherence: take all prescribed medications exactly as directed; do NOT stop baclofen or clonazepam abruptly — this can cause seizures or dangerous withdrawal; report side effects before stopping | - | ROUTINE | ROUTINE |
| Oscillopsia coping strategies: use steady head positioning when reading; increase lighting and contrast; reduce screen time during acute symptoms; sit with back supported to reduce head movement; use large-print materials | - | ROUTINE | ROUTINE |
| Driving restrictions: do NOT drive if experiencing oscillopsia or visual instability; notify your neurologist before resuming driving; formal visual acuity testing may be required for driving clearance | - | ROUTINE | ROUTINE |
| Return to ED immediately if: sudden new weakness, numbness, or difficulty speaking (stroke symptoms); sudden severe headache; sudden vision loss; worsening nystagmus with new neurologic symptoms; severe vomiting preventing medication intake; falls with head injury | STAT | STAT | ROUTINE |
| Activity modification: avoid heights, ladders, and heavy machinery until nystagmus stabilized; use caution on stairs (use handrails); avoid rapid head movements that worsen symptoms; ask for assistance with ambulation if unsteady | ROUTINE | ROUTINE | ROUTINE |
| Vestibular rehabilitation exercises: perform prescribed gaze stabilization exercises daily as instructed by physical therapy; exercises may initially worsen symptoms but improve compensation over time; report persistent worsening to provider | - | ROUTINE | ROUTINE |
| Alcohol avoidance: alcohol worsens nystagmus and impairs vestibular compensation; avoid alcohol completely during active treatment and evaluation | - | ROUTINE | ROUTINE |

### 4C. Lifestyle & Prevention

| Recommendation | ED | HOSP | OPD |
|---------------|:--:|:----:|:---:|
| Home safety assessment: remove trip hazards (loose rugs, cords); install grab bars in bathroom; ensure adequate lighting throughout home; non-slip mats in shower/bathtub | - | ROUTINE | ROUTINE |
| Visual environment optimization: use high-contrast materials for reading; avoid busy visual patterns (striped wallpaper, scrolling screens); use task lighting; matte finishes reduce glare-induced oscillopsia worsening | - | - | ROUTINE |
| Medication review: review all current medications with provider for vestibulotoxic or nystagmus-causing agents; avoid over-the-counter sedating antihistamines; report any new medications to neurologist | - | ROUTINE | ROUTINE |
| Fall prevention program: balance exercises as prescribed by vestibular PT; wear supportive footwear; use assistive device (cane/walker) if recommended; avoid walking in dark or on uneven surfaces | - | ROUTINE | ROUTINE |
| Alcohol and substance avoidance: alcohol worsens nystagmus and impairs cerebellar function; avoid recreational substances that affect vestibular function; chronic alcohol use causes permanent cerebellar degeneration | - | ROUTINE | ROUTINE |
| Low vision support resources: contact local low vision rehabilitation services if oscillopsia affects reading, work, or daily activities; assistive technology (text-to-speech, magnification devices); occupational therapy referral | - | - | ROUTINE |

---

═══════════════════════════════════════════════════════════════
SECTION B: SUPPORTING INFORMATION
═══════════════════════════════════════════════════════════════

## 5. DIFFERENTIAL DIAGNOSIS

### Nystagmus Classification by Waveform

| Type | Waveform | Description | Common Causes |
|------|----------|-------------|---------------|
| **Jerk nystagmus** | Slow drift + fast corrective saccade | Defined by direction of fast phase; most common acquired type | Vestibular (peripheral or central), gaze-evoked, downbeat, upbeat |
| **Pendular nystagmus** | Sinusoidal oscillation (equal velocity both directions) | No fast phase; often multidirectional or circular/elliptical | MS (acquired), oculopalatal tremor, congenital/infantile |
| **Mixed** | Jerk in some positions, pendular in others | Character changes with gaze direction | MS, brainstem lesions |

### Central vs. Peripheral Nystagmus

| Feature | Peripheral | Central |
|---------|-----------|---------|
| **Direction** | Unidirectional (horizontal +/- torsional); fast phase beats AWAY from lesion | Direction-changing, vertical (downbeat/upbeat), purely torsional, or any direction |
| **Effect of fixation** | **SUPPRESSED** by visual fixation (decreases with fixation) | **NOT suppressed** by fixation; may increase |
| **Alexander's law** | Follows Alexander's law (increases in direction of fast phase) | May not follow Alexander's law |
| **Associated symptoms** | Vertigo (often severe), nausea, hearing loss, tinnitus | Vertigo (variable), diplopia, dysarthria, dysphagia, ataxia, focal deficits |
| **Head impulse test** | Abnormal (corrective saccade) | Normal (no saccade) |
| **Skew deviation** | Absent | May be present |
| **Duration** | Resolves over days to weeks (compensation) | May persist or be chronic |
| **Localizing value** | Ipsilateral vestibular nerve or labyrinth | Brainstem, cerebellum, or central vestibular pathways |

### Nystagmus by Type and Localization

| Nystagmus Type | Direction | Localization | Key Causes | Key Features |
|----------------|-----------|-------------|------------|--------------|
| **Downbeat nystagmus** | Fast phase downward; worst in lateral downgaze | Craniocervical junction; cerebellar flocculus/paraflocculus | Chiari malformation (most common structural); cerebellar degeneration; MS; lithium toxicity; Wernicke; anti-GAD65; paraneoplastic | Increases in lateral downgaze; oscillopsia worse looking down (e.g., reading, stairs); convergence-induced upbeat component possible |
| **Upbeat nystagmus** | Fast phase upward | Medulla (paramedian); midbrain; cerebellar vermis | Wernicke encephalopathy; brainstem stroke; MS; brainstem tumor; meningitis | May convert to downbeat; often transient; Wernicke = most treatable cause |
| **Gaze-evoked nystagmus** | Beats in direction of gaze (right-beating on right gaze, left-beating on left gaze) | Cerebellar flocculus (neural integrator); brainstem | **Drug toxicity** (most common: phenytoin, carbamazepine, alcohol, sedatives); cerebellar disease; brainstem lesion; myasthenia gravis (fatigue-related) | Symmetric = drug effect; asymmetric = structural lesion; rebound nystagmus on return to center = cerebellar |
| **Periodic alternating nystagmus (PAN)** | Horizontal jerk that reverses direction every 90-120 seconds with null periods | Cerebellar nodulus/uvula | Chiari malformation; cerebellar degeneration; MS; Creutzfeldt-Jakob disease; lithium toxicity; congenital | **Observe for >2 minutes** to detect; mistaken for gaze-evoked; null period between direction changes; RESPONDS to baclofen |
| **See-saw nystagmus** | One eye rises + intorts while other falls + extorts, then reverses | Parasellar/diencephalic lesion; INC (interstitial nucleus of Cajal) | Parasellar mass (craniopharyngioma, pituitary macroadenoma); brainstem stroke; septo-optic dysplasia | Associated with bitemporal hemianopia (chiasmal compression); pendular variant = brainstem; jerk variant = diencephalic |
| **Convergence-retraction nystagmus** | Eyes converge and retract into orbits on attempted upgaze | Dorsal midbrain (pretectum) | Pineal region tumor; hydrocephalus (tectal compression); MS; brainstem stroke | Part of **Parinaud syndrome** (dorsal midbrain syndrome); associated with upgaze palsy, light-near dissociation, eyelid retraction (Collier sign) |
| **Torsional nystagmus** | Purely rotatory (no horizontal/vertical component) | Medulla (lateral medullary syndrome); midbrain | Wallenberg syndrome (lateral medullary stroke); midbrain lesion | Purely torsional = ALWAYS central; combined horizontal-torsional may be peripheral |
| **Acquired pendular nystagmus** | Sinusoidal, multidirectional or elliptical; no fast phase | Brainstem (pons/medulla) | MS (brainstem demyelination); oculopalatal tremor (inferior olivary nucleus hypertrophy) | MS is most common cause of acquired pendular; responds to gabapentin or memantine; oculopalatal variant associated with palatal myoclonus |
| **Vestibular nystagmus (peripheral)** | Horizontal-torsional, unidirectional | Peripheral vestibular apparatus or nerve | BPPV; vestibular neuritis; labyrinthitis; Meniere's disease; vestibular schwannoma | Suppressed by fixation; follows Alexander's law; positive HIT |
| **Positional nystagmus (BPPV)** | Upbeat-torsional (posterior canal); horizontal (lateral canal) | Semicircular canals (otolith displacement) | BPPV (posterior > lateral > anterior canal) | Latency (2-20 sec); limited duration (<60 sec); fatigable; triggered by specific positions |

### Red Flags Indicating Central Nystagmus

| Red Flag | Concern |
|----------|---------|
| **Direction-changing** nystagmus on gaze | Central vestibular or cerebellar lesion |
| **Vertical nystagmus** (downbeat or upbeat) | Craniocervical junction, brainstem, or cerebellar pathology |
| **Purely torsional** nystagmus | Brainstem lesion (ALWAYS central) |
| **Not suppressed** by visual fixation | Central; peripheral nystagmus always suppresses with fixation |
| **Normal head impulse test** in acute vestibular syndrome | Central cause (stroke) until proven otherwise |
| **Skew deviation** (vertical misalignment) | Brainstem lesion |
| Associated neurologic deficits (diplopia, dysarthria, dysphagia, ataxia) | Brainstem/cerebellar pathology |
| **No latency, non-fatigable** positional nystagmus | Central positional nystagmus (vs. BPPV) |
| **Rebound nystagmus** (direction reversal on return to center from eccentric gaze) | Cerebellar disease |
| **Convergence-retraction** pattern | Dorsal midbrain lesion |

---

## 6. MONITORING PARAMETERS

### ED / Acute Phase

| Parameter | ED | HOSP | OPD | ICU | Frequency | Target | Action if Abnormal |
|-----------|:--:|:----:|:---:|:---:|-----------|--------|-------------------|
| Nystagmus characterization (direction, type, fixation effect) | STAT | STAT | ROUTINE | STAT | On presentation; after interventions | Complete classification; central vs. peripheral determination | Central features — STAT MRI; neurology/stroke consultation |
| Neurologic exam (cranial nerves, cerebellar, motor, sensory) | STAT | STAT | ROUTINE | STAT | On presentation; q2h if central concern | No focal deficits beyond nystagmus | New deficits — stroke workup; expanding lesion |
| Vital signs | STAT | STAT | - | STAT | q1-2h | Stable | Hypertension — stroke concern; hypotension — volume depletion |
| Drug levels (if applicable) | STAT | STAT | ROUTINE | STAT | On presentation | Therapeutic range | Supratherapeutic — hold/reduce medication |
| Electrolytes (Na, Mg, Ca) | STAT | STAT | ROUTINE | STAT | On presentation; q6h if correcting | Normal | Ongoing correction per protocol |
| Visual acuity | STAT | STAT | ROUTINE | - | On presentation | Baseline documentation | Reduced VA with nystagmus — urgent neuro-ophthalmology |

### Inpatient / Subacute Phase

| Parameter | ED | HOSP | OPD | ICU | Frequency | Target | Action if Abnormal |
|-----------|:--:|:----:|:---:|:---:|-----------|--------|-------------------|
| Nystagmus pattern reassessment | - | ROUTINE | - | ROUTINE | Daily | Improving or stable | Worsening — repeat imaging; expanding lesion; new etiology |
| Gait and balance assessment | - | ROUTINE | ROUTINE | - | Daily | Safe ambulation | Persistent imbalance — PT evaluation; fall precautions |
| Treatment response (4-AP, baclofen, gabapentin, memantine) | - | ROUTINE | ROUTINE | - | Daily while titrating | Reduced nystagmus intensity/oscillopsia | No response at therapeutic dose — alternative medication; reassess etiology |
| Side effects of treatment | - | ROUTINE | ROUTINE | - | Daily | Tolerable | Seizure (4-AP) — discontinue; sedation (baclofen/clonazepam) — reduce dose |
| MRI findings correlation | - | ROUTINE | ROUTINE | - | After imaging | Explains nystagmus pattern | Discordance between nystagmus and imaging — expand workup |

### Outpatient Follow-up

| Parameter | ED | HOSP | OPD | ICU | Frequency | Target | Action if Abnormal |
|-----------|:--:|:----:|:---:|:---:|-----------|--------|-------------------|
| Nystagmus reassessment | - | - | ROUTINE | - | 2-4 weeks, then q3 months | Stable or improving | Progressive — repeat imaging; degenerative or autoimmune etiology |
| Visual acuity and oscillopsia severity | - | - | ROUTINE | - | Each visit | Stable or improved | Worsening — medication adjustment; neuro-ophthalmology |
| Treatment efficacy and tolerability | - | - | ROUTINE | - | 2-4 weeks after initiation; then q3 months | Symptom benefit; tolerable side effects | Adjust dose; switch agent; add combination therapy |
| MRI (follow-up) | - | - | ROUTINE | - | 3-6 months if structural lesion; PRN if new symptoms | Stable or resolved | Growth — neurosurgical referral; new lesions — MS, metastases |
| VNG/ENG (follow-up) | - | - | ROUTINE | - | 6-12 months or PRN | Quantitative improvement or stability | Progressive vestibular loss — reassess etiology |
| Vestibular rehabilitation progress | - | - | ROUTINE | - | Monthly during active rehab | Functional improvement in balance and oscillopsia | Plateau — reassess; modify exercises; alternative approaches |

---

## 7. DISPOSITION CRITERIA

### Admission Criteria

| Level of Care | Criteria |
|---------------|----------|
| ICU / Stroke unit | Posterior circulation stroke with acute nystagmus; basilar artery occlusion; cerebellar stroke with mass effect/hydrocephalus; altered consciousness with nystagmus |
| General floor | Acute central nystagmus requiring workup (MRI, vascular imaging); Wernicke encephalopathy requiring IV thiamine; intractable nausea/vomiting/oscillopsia; new neurologic deficits with nystagmus; medication toxicity requiring monitoring |
| Observation | Acute-onset nystagmus pending MRI; nystagmus with equivocal HINTS findings; serial neurologic exams needed |

### Discharge Criteria

| Criterion | Details |
|-----------|---------|
| Etiology established or stroke excluded | Clear peripheral cause (BPPV, vestibular neuritis); OR central cause identified with treatment plan initiated; OR MRI negative with appropriate outpatient follow-up |
| Symptoms manageable | Oscillopsia tolerable; nausea controlled; no significant visual impairment affecting safety |
| Safe ambulation | Walk safely (with or without assistance); low fall risk; adequate home support |
| Treatment initiated | Specific treatment started (4-AP for downbeat, baclofen for PAN, gabapentin for pendular, thiamine for Wernicke, etc.); or medication toxicity corrected |
| Education provided | Nystagmus type explained; treatment plan reviewed; when to return (worsening symptoms, new neurologic deficits, visual loss) |
| Follow-up arranged | Neurology within 1-2 weeks; neuro-ophthalmology if indicated; VNG/audiometry scheduled; vestibular PT if applicable |

### Discharge Prescriptions

| Medication | Indication | Instructions |
|-----------|------------|--------------|
| 4-Aminopyridine 5 mg (compounded) or Dalfampridine 10 mg | Downbeat nystagmus | Take BID; do not exceed prescribed dose; report seizure-like symptoms immediately |
| Baclofen 5-10 mg | PAN or symptomatic nystagmus | Take TID; titrate as directed; do NOT stop abruptly |
| Gabapentin 300 mg | Acquired pendular nystagmus | Take TID; titrate as directed; report excessive sedation or dizziness |
| Meclizine 25 mg | PRN for acute oscillopsia/vertigo (short-term) | Take q6-8h as needed; STOP after 48-72h; for short-term use only |
| Ondansetron 4-8 mg ODT | PRN nausea | Dissolve on tongue as needed |
| Thiamine 100 mg (oral) | Maintenance after IV thiamine course for Wernicke | Take daily indefinitely; continue B-vitamin supplementation |
| Clonazepam 0.5 mg | Refractory oscillopsia (specialist-initiated) | Take BID; avoid driving; do not combine with alcohol; avoid abrupt discontinuation |

---

## 8. EVIDENCE & REFERENCES

### Key Guidelines

| Guideline | Source | Year | Key Recommendation |
|-----------|--------|------|-------------------|
| Eye Movement Abnormalities in Clinical Diagnosis | [Leigh & Zee, The Neurology of Eye Movements, 5th ed.](https://pubmed.ncbi.nlm.nih.gov/26160853/) | 2015 | Comprehensive reference for nystagmus classification and localization; bedside examination techniques |
| HINTS Exam | [Kattah et al.](https://pubmed.ncbi.nlm.nih.gov/19762709/) | 2009 | HINTS more sensitive than early MRI for stroke in acute vestibular syndrome; 100% sensitivity, 96% specificity |
| BPPV Practice Guideline | [AAO-HNS (Bhattacharyya et al.)](https://pubmed.ncbi.nlm.nih.gov/28248609/) | 2017 | Dix-Hallpike gold standard for positional nystagmus diagnosis; Epley maneuver first-line for posterior canal BPPV |
| Cerebellar Nystagmus Treatment | [Strupp et al.](https://pubmed.ncbi.nlm.nih.gov/12847523/) | 2003 | 4-Aminopyridine effective for downbeat nystagmus; first randomized evidence |
| Periodic Alternating Nystagmus | [Halmagyi et al.](https://pubmed.ncbi.nlm.nih.gov/7191854/) | 1980 | Baclofen is effective treatment for PAN; landmark observation |

### Landmark Studies

| Study | Finding | Impact |
|-------|---------|--------|
| [Strupp et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12847523/) | 4-Aminopyridine (4-AP) reduced slow-phase velocity of downbeat nystagmus by ~50% and improved visual acuity in randomized crossover trial | Established 4-AP as first-line treatment for downbeat nystagmus |
| [Claassen et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23460616/) | 4-AP 5 mg TID significantly reduced downbeat nystagmus intensity and oscillopsia vs. placebo in double-blind RCT | Confirmed 4-AP efficacy; defined dosing regimen |
| [Kattah et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19762709/) | HINTS exam (Head Impulse, Nystagmus pattern, Test of Skew) was 100% sensitive and 96% specific for stroke in acute vestibular syndrome | HINTS is standard for all acute vestibular syndrome; nystagmus pattern is key component |
| [Halmagyi et al. (1980)](https://pubmed.ncbi.nlm.nih.gov/7191854/) | Baclofen abolished periodic alternating nystagmus in patients with craniocervical junction disease | Baclofen became standard treatment for PAN |
| [Kalla et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17928582/) | 3,4-Diaminopyridine improved downbeat nystagmus with potentially better safety profile than 4-AP | Alternative aminopyridine option for downbeat nystagmus |
| [Tarnutzer et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21576300/) | Meta-analysis: Individual HINTS components — normal head impulse test most predictive of central cause in acute vestibular syndrome | Direction-changing nystagmus and normal HIT = "dangerous" signs requiring stroke workup |
| [Choi et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30341546/) | 12-20% of posterior fossa strokes missed on early MRI (<48h) but detected on repeat imaging | If high clinical suspicion (central nystagmus pattern) and initial MRI negative, repeat MRI at 48-72h |
| [Wagner et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34115410/) | Systematic review of aminopyridine treatment for cerebellar and oculomotor disorders; confirmed efficacy for downbeat nystagmus and episodic ataxia type 2 | Supports aminopyridine use across cerebellar oculomotor disorders |
| [Dieterich et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/2052574/) | Clonazepam effective for downbeat nystagmus and other forms of central vestibular nystagmus | Clonazepam as second-line option for downbeat nystagmus |
| [Starck et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9109746/) | Gabapentin and memantine both effective for acquired pendular nystagmus in MS patients | Established pharmacotherapy for acquired pendular nystagmus |

### Nystagmus Drug Response Evidence

| Nystagmus Type | First-Line Treatment | Level of Evidence | Key Reference |
|----------------|---------------------|-------------------|---------------|
| Downbeat nystagmus | 4-Aminopyridine | RCT (Level I) | [Strupp et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12847523/); [Claassen et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23460616/) |
| Periodic alternating nystagmus | Baclofen | Case series (Level III) | [Halmagyi et al. (1980)](https://pubmed.ncbi.nlm.nih.gov/7191854/) |
| Upbeat nystagmus | 4-Aminopyridine (trial) | Case reports (Level IV) | [Glasauer et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15721220/) |
| Gaze-evoked (drug-induced) | Remove offending agent | Expert consensus (Level V) | Standard practice |
| Acquired pendular (MS) | Gabapentin or memantine | RCT (Level I) | [Starck et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9109746/) |
| See-saw nystagmus | Treat underlying cause | Case reports (Level IV) | Per etiology |
| Convergence-retraction | Treat underlying cause | Expert consensus (Level V) | Per etiology |
| Vestibular (peripheral) | Treat underlying disorder | Per disorder | See Vertigo/Dizziness template |

---

## CHANGE LOG

**v1.1 (February 2, 2026)**
- Added ICU column to all lab tables (1A, 1B, 1C) per C2
- Added ICU column to all imaging tables (2A, 2B, 2C, LP) per C3
- Added ICU column to all treatment tables (3A, 3B, 3C) — standardized 10-column format per C1
- Split vestibular suppressants into individual rows: meclizine, dimenhydrinate, diazepam, ondansetron per C6/M1
- Replaced all cross-references with full content: upbeat nystagmus 4-AP contraindications, upbeat baclofen contraindications per C4/M3/M4
- Split see-saw nystagmus clonazepam/baclofen into individual rows per C5/M5
- Added ACQUIRED PENDULAR NYSTAGMUS treatment subsection: gabapentin, memantine, treat underlying MS per M6/R3
- Added CONVERGENCE-RETRACTION NYSTAGMUS treatment subsection per M7/R4
- Relabeled Section 4: 4A = Referrals & Consults, 4B = Patient Instructions, 4C = Lifestyle & Prevention per C7/R7
- Created Section 4B Patient Instructions with 8 items including return precautions per C8/R8
- Created Section 4C Lifestyle & Prevention with 6 items per R9
- Added ICU column to Section 4A per S4/R13
- Added venue columns (ED, HOSP, OPD, ICU) to all Section 6 monitoring tables per C9/R10
- Updated frontmatter setting to "ED, HOSP, OPD, ICU" per C10/R11
- Converted directive language throughout — removed "consider", "may", "should" per R12
- Added acquired pendular nystagmus to differential diagnosis table (Section 5)
- Added gabapentin for acquired pendular nystagmus to discharge prescriptions
- Added Starck et al. (1997) to Landmark Studies
- Updated SCOPE to include gabapentin/memantine for acquired pendular nystagmus
- Version incremented from 1.0 to 1.1

**v1.0 (February 2, 2026)**
- Initial template creation
- Comprehensive nystagmus evaluation covering classification (central vs. peripheral), systematic bedside examination, nystagmus subtype differentiation (downbeat, upbeat, PAN, gaze-evoked, see-saw, convergence-retraction, torsional, vestibular), HINTS exam integration, VNG/ENG testing, MRI indications, and type-specific pharmacotherapy (4-AP for downbeat, baclofen for PAN)

---

## APPENDIX A: Systematic Nystagmus Bedside Examination Protocol

**Step 1: Primary Position Observation**
- Observe eyes in primary gaze (straight ahead) for 30+ seconds
- Document: presence of spontaneous nystagmus, direction, waveform (jerk vs. pendular), amplitude, frequency
- Note: Some nystagmus types (PAN) require >2 minutes of observation to detect direction reversal

**Step 2: Gaze Testing (9 Positions)**
- Test gaze in: center, right, left, up, down, right-up, right-down, left-up, left-down
- Document: gaze-evoked nystagmus (direction changes with gaze — central); Alexander's law compliance; rebound nystagmus on return to center
- Hold eccentric gaze for 20-30 seconds at each position

**Step 3: Fixation Removal (Frenzel Goggles or Equivalent)**
- Apply Frenzel goggles (+20 diopter lenses) or use infrared video goggles
- Alternative: Observe fundus with ophthalmoscope (nystagmus direction reversed on fundoscopy)
- **Key principle:** Peripheral nystagmus INCREASES; central nystagmus UNCHANGED or increases

**Step 4: Convergence Testing**
- Have patient fixate on near target (10-15 cm)
- Document effect on nystagmus (convergence dampens some nystagmus types; downbeat may reverse to upbeat; convergence-retraction nystagmus elicited by OKN drum or attempted upgaze)

**Step 5: Head-Shaking Nystagmus**
- Patient closes eyes; examiner oscillates head horizontally (~20 cycles at 2 Hz)
- Open eyes immediately after stopping; observe for nystagmus
- Positive: Nystagmus appears after head shaking — vestibular asymmetry; direction indicates side of lesion (fast phase away from lesion in acute; toward lesion in chronic compensation)

**Step 6: Head Impulse Test (HIT)**
- Patient fixates on examiner's nose
- Small, rapid, unpredictable horizontal head thrusts (10-20 degrees)
- **Abnormal (peripheral):** Corrective saccade (eyes "catch up" after thrust)
- **Normal (central concern):** Eyes stay on target without saccade

**Step 7: Positional Testing**
- Dix-Hallpike maneuver (posterior canal BPPV)
- Supine roll test (horizontal canal BPPV)
- Document: latency, duration, direction, fatigability, nystagmus pattern

**Step 8: Test of Skew (Alternate Cover Test)**
- Patient fixates on target; examiner alternately covers each eye
- Positive: Vertical refixation movement — brainstem lesion (skew deviation)

---

## APPENDIX B: Nystagmus Type Quick Reference

| If You See... | Think... | Next Step |
|---------------|----------|-----------|
| Downbeat nystagmus (worst in lateral downgaze) | Craniocervical junction; cerebellar degeneration; drug toxicity (lithium); Wernicke; anti-GAD65 | MRI brain + craniocervical junction; drug levels; thiamine; anti-GAD65; start 4-AP |
| Upbeat nystagmus | Medullary lesion; Wernicke; MS; brainstem tumor | MRI brain; thiamine empirically; treat cause |
| Direction-changing gaze-evoked nystagmus | Drug toxicity (#1); cerebellar disease; brainstem lesion | Drug levels first; MRI if not drug-related |
| Periodic alternating nystagmus (reverses q90-120 sec) | Cerebellar nodulus lesion; Chiari; CJD; congenital | MRI brain + craniocervical junction; start baclofen |
| Purely torsional nystagmus | ALWAYS central — brainstem (lateral medullary stroke) | STAT MRI with DWI; stroke workup |
| See-saw nystagmus | Parasellar mass; diencephalic lesion | MRI with sellar/parasellar protocol; visual fields; endocrine panel |
| Convergence-retraction nystagmus | Dorsal midbrain (Parinaud syndrome); pineal tumor; hydrocephalus | MRI brain; check upgaze, pupils; neurosurgical referral |
| Unidirectional horizontal-torsional, suppressed by fixation | Peripheral vestibular (neuritis, BPPV, Meniere's) | HINTS exam; Dix-Hallpike; audiometry; treat per disorder |
| Acquired pendular nystagmus | MS (brainstem demyelination); oculopalatal tremor | MRI brain; MS workup; gabapentin or memantine trial |
| Positional with latency + fatigue (<60 sec) | BPPV (posterior or horizontal canal) | Dix-Hallpike confirms; Epley maneuver treats |
| Positional without latency, non-fatigable, persistent | Central positional nystagmus; posterior fossa lesion | MRI brain; NOT BPPV — do not perform repositioning maneuvers |

---

## APPENDIX C: 4-Aminopyridine (4-AP) Prescribing Guide

**Mechanism:** Blocks voltage-gated potassium channels (Kv1 family) — restores Purkinje cell excitability — normalizes cerebellar output to vestibular and oculomotor nuclei

**Indications:**
- Downbeat nystagmus (strongest evidence — Level I)
- Episodic ataxia type 2 (CACNA1A mutation)
- Upbeat nystagmus (limited evidence)
- Gaze-evoked nystagmus from cerebellar disease (limited evidence)

**Dosing:**
- Compounded 4-AP: 5 mg PO BID (standard); titrate to 5 mg TID (max 15-20 mg/day)
- Dalfampridine (Ampyra, sustained-release): 10 mg PO BID (12 hours apart); do NOT crush or split extended-release tablets
- Onset of effect: 30-60 minutes; duration 4-6 hours (immediate-release), 12 hours (sustained-release)

**Contraindications:**
- Seizure disorder (absolute — lowers seizure threshold)
- CrCl <50 mL/min (dose adjustment or avoid — renally cleared)
- Concurrent use of other 4-AP formulations (overdose risk)
- Cardiac arrhythmia (QT prolongation at supratherapeutic doses)

**Monitoring:**
- ECG at baseline
- Renal function at baseline and periodically
- Clinical response assessment at 2-4 weeks (video recording of nystagmus helpful)
- Visual acuity measurement (reading chart at distance)
- Patient seizure diary

**Side Effects:** Insomnia, paresthesias, headache, dizziness, nausea, seizure (dose-dependent, typically at >20 mg/day)

---

## APPENDIX D: HINTS Exam Interpretation for Nystagmus Evaluation

**Prerequisites:**
- Patient has **ACUTE VESTIBULAR SYNDROME**: Continuous vertigo >24h, nausea/vomiting, nystagmus, gait instability
- Spontaneous nystagmus visible at rest or with fixation removed
- Examiner is trained in HINTS

| Component | Peripheral (Safe) | Central (Dangerous) |
|-----------|-------------------|---------------------|
| **Head Impulse Test** | ABNORMAL — corrective saccade (reassuring) | NORMAL — no saccade (dangerous) |
| **Nystagmus** | Unidirectional — fast phase always same direction (reassuring) | Direction-changing, vertical, or purely torsional (dangerous) |
| **Test of Skew** | Negative — no vertical misalignment (reassuring) | Positive — vertical refixation (dangerous) |

**ANY ONE central sign = Central lesion likely — STAT MRI + stroke workup**
**ALL THREE peripheral = Peripheral vestibular lesion (vestibular neuritis)**

**INFARCT Mnemonic:** **I**mpulse **N**ormal, **F**ast-phase **A**lternating, **R**efixation on cover **T**est = Central = Stroke until proven otherwise

**Important:** HINTS is ONLY valid in the acute vestibular syndrome (continuous vertigo/nystagmus >24h). It is NOT valid for episodic, positional, or chronic nystagmus.

---

*This template has been validated through the checker pipeline (v1.1) and requires physician review before clinical deployment.*
